HRA Pharma (France) and Gedeon Richter (Hongrie) ont signé un accord de Marketing et de Distribution

Paris, France and Budapest, Hungary – February 17, 2009 – HRA Pharma (www.hra-pharma.com) and Gedeon Richter Plc announced today that they have entered into a marketing and distribution agreement in the area of reproductive health. Under the agreement, Gedeon Richter will market and distribute HRA Pharma’s product ella® / ellaOne® in Central Eastern Europe (CEE) and the Commonwealth of Independent States (CIS), enabling women in these areas to have greater control over their own contraception.

HRA Pharma will supply ella® / ellaOne® to Gedeon Richter for marketing and distribution in 7 CEE countries (Bulgaria, Czech Republic, Hungary, Poland, Romania, Serbia and Slovakia) and the 12 CIS nations (Azerbaijan, Armenia, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Uzbekistan and Ukraine). Developed by HRA Pharma, ella® / ellaOne® is an innovative, next generation emergency contraceptive based on the new chemical entity ulipristal acetate. The product is still undergoing evaluation by health authorities and is awaiting regulatory approvals. No financial terms of the agreement were disclosed.

Plus d'information sur le site suivant:

http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=5689